Bayer vs Corteva after Q1, the Supreme Court win and 1.97 million euros of insider buying

Bayer is not being traded like a sleepy European healthcare conglomerate right now. It is being traded like a litigation story with a crop science business attached, and that distinction matters when you put it next to Corteva. Corteva gives you the cleaner read on agricultural demand and product execution. Bayer gives you the messier one, but also the one with more moving parts, more optionality, and more ways for the market to misprice a turn.

The stock was around EUR 48.46 on July 17, up about 1.55% intraday from a prior close near EUR 47.72, according to Reuters and CNBC. That move came in a week with limited fresh company-specific catalysts, which is usually when the market falls back on the last real event. For Bayer, the last real event was not a routine earnings print. It was the U.S. Supreme Court ruling on June 25 that favored the company in Roundup-related preemption matters, a decision Reuters said helped drive a sharp rally at the time. Corteva did not have that kind of legal repricing hanging over it. That is the first difference, and it is not a small one.

Bayer’s Q1 2026 report on May 12 gave the market a cleaner operating backdrop than the stock’s long-term reputation would imply. Group sales were EUR 13.4bn, up 4.1% on a currency- and portfolio-adjusted basis. Crop Science EBITDA before special items rose 13% to EUR 3.0bn after the company resolved a soy licensing dispute with Corteva. Core earnings per share reached EUR 2.71. Those are not rescue numbers, but they are not the numbers of a business in operational freefall either. Corteva, by contrast, remains the easier name to own if you want agricultural exposure without the legal baggage. That is the comparison the market keeps making, whether it says it out loud or not.

The Q1 print gave Bayer a floor, Corteva gave the sector a cleaner benchmark

Bayer’s first-quarter numbers matter because they showed the business can still produce operating momentum while the legal overhang remains unresolved. The Crop Science division was the standout, and the soy licensing resolution with Corteva was not just a footnote. It removed one source of friction and let the segment show through in the numbers. When a crop business posts a 13% rise in EBITDA before special items to EUR 3.0bn, you do not need to dress it up. You need to ask whether the market has already priced the improvement, or whether it is still treating the whole group as a litigation proxy.

Corteva sits on the other side of that trade. It is the named comparator in the licensing dispute, and it is the cleaner benchmark for what a less encumbered crop science name can look like. If you want to know whether Bayer deserves a rerating, Corteva is the obvious reference point because it strips out the legal noise and leaves you with product, pricing, and execution. Bayer’s problem is that the market has spent years assigning a discount for reasons that are not all tied to the current quarter. The June Supreme Court ruling helped, but one ruling does not erase the accumulated skepticism.

Management’s guidance matters here because it tells you what the company itself thinks it can control. Bayer confirmed full-year 2026 guidance for stable sales and adjusted EBITDA in the EUR 9.6bn to EUR 10.1bn range on a currency-adjusted basis. Free cash flow is still projected negative because roughly EUR 5bn in litigation payouts are expected. That is the tension in one line. The operating business can hold up, but cash generation still bends around legal payments. Corteva does not have to carry that burden in the same way, which is why the peer comparison is useful and also unfair in a very specific, market-pricing sense.

The market has not been waiting for a perfect operating story. It has been waiting for evidence that the worst legal outcomes are becoming less likely and that the crop business can keep earning its keep. Bayer gave it both in the span of a few weeks, first through the Q1 report and then through the Supreme Court ruling. The share price response was not linear, because it never is with a name like this. But the direction of travel is clearer than it was in the spring.

What the insiders did while the stock was still carrying a discount

Insider activity over the past 90 days shows net buying of about EUR 1.97m across two transactions, according to the disclosures summarized in InsiderTrades data and the company’s manager transaction filings. That is the part of the story that deserves attention, because it tells you what the board and senior management were willing to do while the stock still traded under the shadow of litigation and before the June ruling had fully settled into the tape. The filing record does not tell you why they bought. It does tell you they bought.

That matters more at Bayer than it would at a cleaner industrial or consumer name. When a company has spent years under legal pressure, insider buying can be a simple expression of valuation, or it can be a sign that the people with the most direct view of the business think the market is still too pessimistic about the cash engine. You should not overread it. You also should not flatten it into background noise. Two transactions and EUR 1.97m of net buying is not a token gesture. It is enough to say the insiders were not hiding from the stock at a moment when many outside holders were still treating it as a litigation chart.

Our scoring puts that activity in context, and the historical T+90 cohort return for this role and size bucket is 1.97%. That is historical cohort data, not a forecast for Bayer, and it is not a promise that this trade will behave the same way. It is simply the average follow-through we have seen in comparable filings. In a name like Bayer, where the legal backdrop can dominate the price action for weeks at a time, that historical read is useful mainly as a reminder that insider buying has tended to be modestly constructive, not magical.

The comparison with Corteva sharpens the point. Corteva does not need insider buying to explain its relative appeal. Bayer does, because the stock still trades with a discount that has to be justified or challenged. When insiders buy into that discount, they are effectively saying the market may be overdoing the penalty. That is not the same as saying the stock is cheap in a vacuum. It is saying the gap between price and operating reality may be wider than the market has been willing to admit.

Bayer’s legal overhang is still the main reason Corteva looks cleaner

Bayer’s June 25 Supreme Court win changed the tone, but it did not remove the legal overhang from the model. Reuters reported that the ruling favored Bayer in Roundup-related preemption matters and helped trigger a sharp share rally. That kind of move is what happens when a market has been waiting for any credible sign that the legal path may be less punishing than feared. The problem is that litigation risk does not disappear because one ruling goes your way. It narrows, it shifts, it gets repriced. It does not vanish.

That is where Corteva remains the cleaner peer. If you are comparing the two on pure agricultural exposure, Corteva gives you the simpler story. Bayer gives you the agricultural story plus the legal one, and the legal one still shapes free cash flow expectations. Management’s own guidance makes that plain by flagging roughly EUR 5bn in expected litigation payouts and negative free cash flow for 2026. The market can live with negative free cash flow for a while if it believes the payout path is visible and bounded. It gets less patient when the legal path keeps changing shape.

The Q1 crop science improvement is what keeps Bayer in the conversation. A 13% rise in Crop Science EBITDA before special items to EUR 3.0bn is not a trivial number, especially after the soy licensing dispute with Corteva was resolved. That dispute resolution matters because it removes one of the cleaner operational objections to the stock. If the crop business can keep delivering while the legal cloud slowly thins, the valuation gap to Corteva becomes harder to defend on fundamentals alone. Harder, yes. Not impossible. The market still has a long memory with Bayer.

The July trading action suggests that memory is still active. The stock’s modest gain around EUR 48.46 on July 17 came in a week without a fresh company event to force a new view. That means the market was still digesting the earlier legal and earnings developments rather than moving on to a new catalyst. Corteva, by contrast, is usually judged on a more ordinary cadence, which is exactly why it often screens better in relative terms. Ordinary can be a premium when the alternative is a legal overhang.

The insider record says Bayer’s own people were willing to lean in

The insider record is not the thesis, but it is the check. Bayer’s net buying of about EUR 1.97m across two transactions over the past 90 days is the kind of activity that tells you the internal temperature was not cold. That is especially relevant after a quarter in which the company showed operating progress and after a Supreme Court ruling that improved the legal tone. If insiders had been selling into that sequence, the comparison with Corteva would look different. They were not.

There is a temptation to turn that into a grand statement about confidence. Resist it. Insider buying can reflect many things, including valuation discipline, portfolio rebalancing, or a desire to signal support. What matters is the timing relative to the stock’s own backdrop. Bayer’s insiders bought while the company was still carrying a litigation discount and before the market had fully absorbed the June ruling. That makes the activity more interesting than a buy after a clean breakout. It does not make it predictive.

The broader pattern also matters. In a company with Bayer’s size and complexity, director-level or executive buying tends to matter most when it appears against a difficult backdrop rather than after the easy money has already been made. That is the case here. The stock had already been through a sharp legal-driven rally in late June, but it was still trading with plenty of skepticism in early July. The insiders did not wait for the market to declare victory. They bought while the argument was still live.

Corteva gives you a useful foil here because it does not need the same kind of insider read to explain its relative simplicity. Bayer’s insiders are buying into a more complicated setup, one where the operating business is improving but the legal cash drain still constrains the equity story. That is why the filing matters. It shows the people with the most direct exposure to the company were willing to own more of it when the market was still pricing the worst of the legal narrative.

What to watch before Bayer reports again on August 4

Bayer’s next scheduled checkpoint is the second-quarter results on August 4, according to the company’s events calendar. That date matters because it is the next chance for management to show whether the Q1 crop science strength was a one-quarter clean-up after the Corteva dispute or the start of a more durable run. It is also the next chance to see whether the June Supreme Court ruling has changed anything meaningful in the company’s legal and cash-flow framing.

Between now and then, the comparison with Corteva stays useful because it keeps the focus on what Bayer still has to prove. Corteva does not need a legal repricing to support its case. Bayer does. The market will be watching whether the company can keep sales stable, hold adjusted EBITDA in the guided EUR 9.6bn to EUR 10.1bn range, and avoid fresh surprises on litigation. If it does, the stock can keep closing the gap to the cleaner peer. If it does not, the discount will look deserved again very quickly.

The insider record will matter less than the operating and legal updates, but it will not disappear from view. Two transactions and EUR 1.97m of net buying are enough to keep the question open: did insiders buy because they saw value after a long period of punishment, or because they believed the June ruling and Q1 print had changed the odds? You do not need to answer that perfectly to use the signal. You only need to know it sits on the bullish side of the ledger.

Bayer versus Corteva, with the legal discount still doing the work

If you strip the story down to the comparison that matters, Bayer is the more complicated name with the more interesting upside if the legal path keeps improving. Corteva is the cleaner name with the easier operating read. That is why the market keeps using Corteva as the benchmark. Bayer’s Q1 numbers, the June Supreme Court ruling, and the insider buying all point in the same direction, but they do not erase the fact that the stock still trades under a litigation cloud and that free cash flow remains pressured by expected payouts.

The useful way to read the setup is not to ask whether Bayer has become a simple story. It has not. The better question is whether the market is still pricing it as if the worst legal and operational outcomes are the base case. The answer looks less obvious after Q1 and after the Supreme Court ruling than it did in May. The insider filings add one more data point in the same direction. They do not settle the argument. They do tell you the argument is not one-sided.

Corteva remains the cleaner peer because it does not have to carry the same legal baggage, and that is why Bayer still has work to do if it wants a sustained rerating. August 4 will give the market the next hard read on whether the company can keep the crop science momentum and keep the legal story from reasserting itself. Until then, the stock sits in the gap between a better operating quarter and a still-expensive legal history.

This is not investment advice.